Wednesday, July 8, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “roflumilast” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 20
Total indexed 20,548
Sponsors 1,769

Quick answer

Showing 20 pipeline programs matching "roflumilast" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

20 results for “roflumilast” Back to intelligence hub

Search results

  1. Roflumilast

    AstraZeneca

    Asthma

    phase 3 small molecule completed

    1 trial
  2. Roflumilast

    AstraZeneca

    COPD

    phase 3 small molecule completed

    1 trial
  3. Roflumilast 0.3% cream

    Arcutis Biotherapeutics

    Chronic Plaque Psoriasis

    phase 3 small molecule completed

    1 trial
  4. Roflumilast Cream

    Arcutis Biotherapeutics

    Atopic Dermatitis Eczema

    phase 3 small molecule completed

    1 trial
  5. Roflumilast Cream 0.05%

    Arcutis Biotherapeutics

    Atopic Dermatitis Eczema

    phase 3 small molecule completed

    1 trial
  6. Roflumilast Cream 0.15%

    Arcutis Biotherapeutics

    Atopic Dermatitis Eczema

    phase 3 small molecule completed

    1 trial
  7. Roflumilast Foam

    Arcutis Biotherapeutics

    Seborrheic Dermatitis

    phase 3 small molecule completed

    1 trial
  8. Roflumilast Foam 0.3%

    Arcutis Biotherapeutics

    Scalp Psoriasis

    phase 3 small molecule completed

    1 trial
  9. Topical roflumilast

    Arcutis Biotherapeutics

    Chronic Plaque Psoriasis

    phase 3 small molecule completed

    1 trial
  10. Roflumilast

    Takeda

    Chronic Obstructive Pulmonary Disease

    phase 2 small molecule terminated

    1 trial
  11. Roflumilast

    Arcutis Biotherapeutics

    Plaque Psoriasis

    phase 2 small molecule completed

    1 trial
  12. Roflumilast Cream 0.05%

    Arcutis Biotherapeutics

    Atopic Dermatitis

    phase 2 small molecule completed

    1 trial
  13. Roflumilast Cream 0.3%

    Arcutis Biotherapeutics

    Plaque Psoriasis

    phase 2 small molecule completed

    1 trial
  14. Roflumilast Foam 0.3%

    Arcutis Biotherapeutics

    Seborrheic Dermatitis

    phase 2 small molecule completed

    1 trial
  15. Roflumilast foam 0.3%

    Arcutis Biotherapeutics

    Plaque Psoriasis

    phase 2 small molecule completed

    1 trial
  16. Roflumilast topical 0.3% foam

    Arcutis Biotherapeutics

    Non-segmental Vitiligo

    phase 2 small molecule active

    1 trial
  17. Topical roflumilast 0.3% foam

    Arcutis Biotherapeutics

    Hidradenitis Suppurativa

    phase 2 small molecule active

    1 trial
  18. Roflumilast

    Takeda

    Schizophrenia

    phase 1 small molecule completed

    1 trial
  19. Roflumilast Cream 0.15%

    Arcutis Biotherapeutics

    ITCH

    approved small molecule active

    1 trial
  20. Roflumilast alternated days

    Lxo Ireland Designated Activity Company

    Chronic Obstructive Pulmonary Disease (COPD)

    approved small molecule completed

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.